AKTS

$19.44+0.44 (+2.32%)

Pre-Market$19.16-0.28 (-1.44%)· Last close May 5

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO